Entrada Therapeutics, Inc. (TRDA): Price and Financial Metrics
TRDA Price/Volume Stats
| Current price | $14.00 | 52-week high | $24.38 |
| Prev. close | $13.14 | 52-week low | $6.04 |
| Day low | $13.19 | Volume | 54,600 |
| Day high | $14.09 | Avg. volume | 47,942 |
| 50-day MA | $13.56 | Dividend yield | N/A |
| 200-day MA | $14.77 | Market Cap | 464.76M |
TRDA Stock Price Chart Interactive Chart >
Entrada Therapeutics, Inc. (TRDA) Company Bio
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest TRDA News From Around the Web
Below are the latest news stories about ENTRADA THERAPEUTICS INC that investors may wish to consider to help them evaluate TRDA as an investment opportunity.
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceBOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA. The fireside chat will be held on Wednesday, |
Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EstimatesThe analysts covering Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) delivered a dose of negativity to shareholders today... |
Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowIt's been a good week for Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders, because the company has just... |
Entrada Therapeutics Reports First Quarter 2023 Financial Results- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 -- Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent busines |
We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth CarefullyWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
TRDA Price Returns
| 1-mo | 20.79% |
| 3-mo | 16.67% |
| 6-mo | -26.59% |
| 1-year | 76.54% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 3.55% |
| 2022 | -21.03% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...